Weight loss injections have been linked to a potential risk of sudden blindness, as warned by the UK regulator following concerns raised by Robbie Williams about his deteriorating vision due to the injections.
The Medicines and Healthcare products Regulatory Agency (MHRA) has advised individuals using semaglutide injections to seek immediate medical attention if they experience sudden blurry or cloudy vision. This caution comes after reports of a rare side effect called non-arteritic anterior ischemic optic neuropathy (NAION) associated with these injections.
NAION can lead to rapid vision loss in one eye due to decreased blood flow to the front part of the optic nerve. Semaglutide, available as Wegovy for weight loss and Ozempic for treating Type 2 diabetes, has been identified as the medication in question.
While the risk of NAION from semaglutide is extremely low, affecting potentially one in 10,000 individuals on the injections, the MHRA urges vigilance. Singer Robbie Williams, an advocate for weight loss injections, has reported worsening vision attributed to the injections, emphasizing the importance of awareness and research before starting such treatments.
Approximately two million people in the UK are estimated to be using weight-loss injections, with semaglutide leading the market. Dr. Alison Cave, Chief Safety Officer at the MHRA, underscores the agency’s commitment to monitoring the safety of all licensed medicines and advises prompt reporting of any vision changes while on semaglutide.
The mechanism behind how weight loss injections like Ozempic, Wegovy, and Mounjaro might trigger NAION remains unclear. These injections, administered weekly, mimic a hormone called glucagon-like peptide 1 (GLP-1) to control hunger and induce weight loss, often resulting in significant weight reduction and various health benefits.
Although these injections may cause side effects such as nausea and stomach discomfort, personalized support is crucial to sustain weight loss. Discontinuing the injections without significant lifestyle changes can lead to weight regain, with lost muscle mass usually not fully recovered. Additional information on potential side effects and proper use of semaglutide is available through the MHRA.
Novo Nordisk, the manufacturer of semaglutide, emphasizes patient safety and close collaboration with regulatory bodies to monitor drug safety. Updates to product information have included NAION as a potential adverse event, with a very rare occurrence rate of up to 1 in 10,000 individuals using semaglutide. The company maintains that the overall benefits of semaglutide outweigh any perceived risks.
